EDIT Editas Medicine, Inc. - 8-K

Item 7.01 Regulation FD Disclosure.

On May 26, 2026, Editas Medicine, Inc. (the “Company”)
issued a press release titled “Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a),
and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress”, a copy of which is furnished as Exhibit 99.1
hereto.

The information in this Item 7.01, including Exhibit 99.1 attached
hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth
by specific reference in such filing.

Item 8.01 Other Events.

On May 25, 2026, the Company announced in an oral presentation at the
94 th European Atherosclerosis Society (EAS) Congress new preclinical data for EDIT-401, its lead in vivo development
candidate, from preclinical studies in non-human primates (“NHPs”). In the data presented, EDIT-401 achieved robust reductions
in LDL-cholesterol (“LDL-C”), lipoprotein(a) (“Lp(a)”), and apolipoprotein B (“ApoB”). The findings
presented included:

·

A single dose of EDIT-401 achieved a 90% or greater mean reduction in
LDL-C, with rapid and dose-dependent effect, across a dose range and with durability through six months.

·

A single dose of EDIT-401 achieved rapid, dose-dependent mean reduction
of approximately 90% in Lp(a), an independent risk factor for atherosclerotic cardiovascular disease (“ASCVD”).

·

A single dose of EDIT-401 achieved rapid, dose-dependent mean reduction
of approximately 90% in ApoB, a key measure of total plaque-causing cholesterol particles and predictive measure for ASCVD.

·

The reductions in LDL-C, Lp(a), and ApoB were highly correlated, supporting
a unified mechanism facilitated by upregulation of the LDL receptor.

The Company continues to advance preclinical studies for EDIT-401,
including an ongoing Good Laboratory Practice (“GLP”) toxicology study in NHPs. Interim results from this study were consistent
with the Company’s other preclinical studies, each of which demonstrated EDIT-401 was well-tolerated at the therapeutically relevant
dose of 1.5 mg/kg with no adverse clinical observations, no notable treatment-related liver enzyme elevations, and no liver histopathology
findings in non-GLP toxicology. EDIT-401 showed low functional liver editing rates with a mean of 12.4% at the therapeutically relevant
dose of 1.5 mg/kg. Low editing was detected in the adrenal gland, spleen and ovary, and no significant editing was observed in any other
of 31 total extrahepatic tissues compared to the vehicle control. Doses of 3 mg/kg and 6 mg/kg, which are greater than the therapeutically
relevant dose, were also evaluated. There were minimal to marked liver enzyme increases and non-adverse liver findings in NHPs administered
3 mg/kg and adverse clinical observations were observed in one NHP at the highest dose of 6 mg/kg.

The Company plans to submit a Clinical Trial Notification (“CTN”)
in Australia to the Therapeutic Goods Administration (TGA) in mid-2026, with the goal of initiating a first-in-human clinical trial of
EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia (“HeFH”) later in 2026 and expects to have early in vivo
human proof of concept data for EDIT-401 by the end of 2026. The Company anticipates that the clinical trial will initially be designed
as a two-part Phase 1/2 trial. Part 1 is expected to be a single ascending dose, dose-finding study and is expected to enroll approximately
18 patients with HeFH in three dosing arms. Eligible patients will have a clinical diagnosis of HeFH with an elevated LDL-C despite treatment
with two or more lipid lowering therapies. The Company plans to complete enrollment of Part 1 and have topline data results available
in 2027. The Company expects that Part 2 of the trial will be a single-dose randomized, placebo-controlled expansion study with approximately
28 patients, and that if the data from the Phase 1/2 trial warrant advancing EDIT-401, the Company would advance EDIT-401 into a single,
pivotal randomized, placebo-controlled Phase 3 clinical trial in patients with HeFH, with or without existing ASCVD or coronary artery
disease. These clinical trial plans are subject to further discussion and alignment with regulatory authorities.

The Company also received pre-IND feedback from the U.S. Food and Drug
Administration (“FDA”) on its nonclinical package, CMC plans, and study design to support an Investigational New Drug Application
(“IND”) for EDIT-401, which the Company believes provides optionality for submitting an IND supportive of the Company’s
anticipated clinical development strategy.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements
and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “target,” “should,” “would,”
and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these
identifying words. Forward-looking statements in this Current Report on Form 8-K include statements regarding the initiation, timing,
progress and results of the Company’s preclinical studies and its research and development programs, including initiating a first-in-human
study for EDIT-401 in 2026 and achievement of early in vivo human proof-of-concept data for EDIT-401 by the end of 2026; the potential
of, and expectations for, EDIT-401; and the timing or likelihood of regulatory filings and approvals, including submitting a CTN in Australia
by mid-2026 for EDIT-401. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking
statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially
from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including:
uncertainties inherent in the initiation and completion of preclinical studies and clinical trials; availability and timing of results
from preclinical studies and clinical trials; uncertainties relating to planned regulatory submissions to initiate clinical trials, including
that results of preclinical studies will warrant such submissions or that regulatory agencies may require additional preclinical studies,
that regulatory submissions shall occur on the expected timelines and that regulatory authorities will provide clearance for trials to
be initiated; that the results and outcome of preclinical studies may not be predictive of the results of clinical trials; and the availability
of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These
and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent
Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company’s subsequent
filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission
in the future. Any forward-looking statements contained in this Current Report on Form 8-K represent the Company’s views only as
of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company
explicitly disclaims any obligation to update any forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.

Description

99.1

Press release issued by the Company on May 26, 2026*

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

*This exhibit shall be deemed to be furnished and not filed.